Novo Nordisk Shares Plunge on Insulin's FDA Failure
Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
UBS's Emanuel: I See Oil at $70 by End of 2018
43:20 - Despite a year of turmoil, Canadian and U.S. equity markets have been performing rather well. Will the bull run continue or has it run out of steam? Julian Emanuel, equity research strategist at UBS, talks equities and oil on "The Daily Brief." (Source: Bloomberg)